Disease X: The 100 Days Mission to End Pandemics | Agenda Bookshop Skip to content
Selected Colleen Hoover Books at €9.99c | In-store & Online
Selected Colleen Hoover Books at €9.99c | In-store & Online
A01=Kate Kelland
A23=Tony Blair
Age Group_Uncategorized
Age Group_Uncategorized
Author_Kate Kelland
automatic-update
Category1=Non-Fiction
Category=MBN
Category=MJCJ
Category=PDZ
Category=PSGL
COP=United Kingdom
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€10 to €20
PS=Active
softlaunch

Disease X: The 100 Days Mission to End Pandemics

English

By (author): Kate Kelland

Engaging, accessible and ultimately optimistic account - BBC Medical Editor Fergus Walsh

DISEASE X sets out a game-changing plan for how the world can learn from Covid-19 and be ready for the next pandemic. - Tony Blair, former British Prime Minister

DISEASE X is a fast-paced, almost real-time account of how international scientists and global public health leaders are preparing the world to be able to contain outbreaks of new and re-emerging infectious diseases before they spawn deadly global contagions like Covid-19.

Disease X is the codename given by the World Health Organisation to a pathogen currently unknown to science that could cause havoc to humankind. Emerging infections are sending us multiple warnings that another Disease X is looming.

These events are not freak events, but are happening continually, and at an increasing cadence: SARS in 2002, H5N1 bird flu in 2004, H1N1 swine flu in 2009, MERS in 2012, Ebola in 2014, Zika in 2015, Covid-19 in 2019, and H5N1 bird flu and mpox more recently.

Written by a long-standing ex-Reuters global health and science correspondent, DISEASE X uses privileged access to the body leading international efforts to control viral outbreaks, the Coalition for Epidemic Preparedness Innovations (CEPI), and its CEO, Dr Richard Hatchett. CEPI seed-funded three successful Covid vaccines, including the AstraZeneca and Moderna shots.

Weaving in insights from the likes of Bill Gates, Erna Solberg, Jeremy Farrar and Seth Berkley, the book explores the emergence of the novel coronavirus and the deadly crisis it caused. It analyses the responses of global health organisations and experts, including the WHO; national governments in Britain, China and the USA; COVAX, the global vaccine allocation facility; pharmaceutical companies; and leading research scientists.

Ultimately, DISEASE X tells how, throughout the devastation of Covid, science and human ingenuity have shown that the world can devise intricate new weapons at a breathtaking pace against new deadly diseases.

It tells how the worlds public health scientists are embarking on a 100 Days Mission to embed that scientific progress into a pandemic-busting plan to defuse future threats from as-yet-unknown pathogens in a little over three months. This is the 100 Days Mission backed by the G7 and G20 - that will see a newly prepared world, one that can move at speed to snuff out future threats before they become deadly pandemics.

With a foreword by former British Prime Minister Tony Blair.

Reviews

DISEASE X sets out how a mystery pathogen of the future could be contained before it goes global, but only if lessons are learned from SARS-CoV-2 and other global disease threats. An engaging, accessible and ultimately optimistic account of how nations, institutions and the scientific community responded to Covid and how they could work together in future.  Fergus Walsh, BBC Medical Editor 

As Kelland argues cogently, fear of the next outbreak should not paralyse us but instead galvanise us into making sure the terrible toll of Covid-19 is not repeated. DISEASE X is a valuable policy roadmap in a world custom-built for pandemics.  Anjana Ahuja, co-author of Spike: The Virus Vs The People

With access to key players on the frontlines, DISEASE X takes us inside the effort to prevent future outbreaks from exploding into global disasters... this important book outlines why it will be vital to keep pandemic threats at the top of our priority list for decades to come.  James Paton, former Health Correspondent for Bloomberg News

See more
Current price €18.99
Original price €19.99
Save 5%
A01=Kate KellandA23=Tony BlairAge Group_UncategorizedAuthor_Kate Kellandautomatic-updateCategory1=Non-FictionCategory=MBNCategory=MJCJCategory=PDZCategory=PSGLCOP=United KingdomDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€10 to €20PS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Weight: 295g
  • Dimensions: 156 x 234mm
  • Publication Date: 15 Feb 2024
  • Publisher: Canbury Press
  • Publication City/Country: United Kingdom
  • Language: English
  • ISBN13: 9781912454976

About Kate Kelland

Kate Kelland is an award-winning global health correspondent formerly at Reuters. She is now chief scientific writer at the Coalition for Epidemic Preparedness Innovations in London. During 30 years in journalism she set the agenda in global health and science coverage. In 2017 she won the London Foreign Press Association Science Story of the Year award for her investigative reporting on the International Agency for Research on Cancer. In 2016 she won the Medical Journalists Associations Feature of the Year award for a piece on the critical challenge facing the WHO to heal itself. She was UK winner of the European Health Prize for Journalists in 2011 2012 and 2013. Tony Blair is Executive Chairman of the Tony Blair Institute for Global Change. He was Prime Minister of the United Kingdom from 1997 to 2007 and leader of the Labour Party between 1994 and 2007. He led the Labour Party to three consecutive general election victories in 1997 2001 and 2005 becoming the longest-serving prime minister in modern times after Margaret Thatcher. The Tony Blair Institute for Global Change aims to equip political leaders around the world to build prosperous open and inclusive societies.      

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept